Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucocorticoid-tapering maintenance therapy with belimumab in systemic lupus erythematosus
jRCTs071190045Active, not recruiting
- Sponsor
- GSK
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of belimumab in systemic lupus erythematosus (SLE), sponsored by GSK. Primary endpoint: Proportion of subjects who achieve glucocorticoid-free status at Week 24. Started Feb 2020; status: active, not recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCTs071190045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190045.